PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsAdenocarcinoma
MeSH D000230 - adenocarcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D002277:Carcinoma
18 Companies
3 Drugs
$
Success rate
D000230: 
Adenocarcinoma
24 Companies
3 Drugs
$
Success rate
D000077192:Adenocarcinoma of lung
0 Companies
0 Drugs
Success rate
D000231:Papillary adenocarcinoma
0 Companies
0 Drugs
Success rate
D002276:Carcinoid tumor
2 Companies
2 Drugs
$
Success rate
D002285:Intraductal carcinoma noninfiltrating
0 Companies
0 Drugs
Success rate
D002288:Mucinous adenocarcinoma
0 Companies
0 Drugs
Success rate
D002292:Renal cell carcinoma
56 Companies
26 Drugs
$
Success rate
D002293:Scirrhous adenocarcinoma
0 Companies
0 Drugs
Success rate
D002822:Choriocarcinoma
36 Companies
5 Drugs
$
Success rate
D003528:Adenoid cystic carcinoma
0 Companies
0 Drugs
Success rate
D003536:Cystadenocarcinoma
0 Companies
0 Drugs
Success rate
D006528:Hepatocellular carcinoma
16 Companies
12 Drugs
$
Success rate
D010145:Extramammary paget disease
41 Companies
6 Drugs
$
Success rate
D011648:Ovine pulmonary adenomatosis
0 Companies
0 Drugs
Success rate
D018262:Clear cell adenocarcinoma
0 Companies
0 Drugs
Success rate
D018263:Follicular adenocarcinoma
0 Companies
0 Drugs
Success rate
D018266:Sebaceous adenocarcinoma
0 Companies
0 Drugs
Success rate
D018267:Acinar cell carcinoma
0 Companies
0 Drugs
Success rate
D018268:Adrenocortical carcinoma
2 Companies
1 Drug
$
Success rate
D018269:Endometrioid carcinoma
0 Companies
0 Drugs
Success rate
D018273:Islet cell carcinoma
7 Companies
2 Drugs
$
Success rate
D018275:Lobular carcinoma
0 Companies
0 Drugs
Success rate
D018277:Mucoepidermoid carcinoma
0 Companies
0 Drugs
Success rate
D018278:Neuroendocrine carcinoma
0 Companies
0 Drugs
Success rate
D018279:Signet ring cell carcinoma
0 Companies
0 Drugs
Success rate
D018280:Skin appendage carcinoma
0 Companies
0 Drugs
Success rate
D018281:Cholangiocarcinoma
3 Companies
3 Drugs
$
Success rate
D044584:Ductal carcinoma
0 Companies
0 Drugs
Success rate
D057090:Eccrine porocarcinoma
0 Companies
0 Drugs
Success rate
D065311:Adenocarcinoma in situ
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaDocetaxel Docetaxel Teva  2010-01-26   
MylanDocetaxel Docetaxel Mylan  2012-01-31   
SanofiDocetaxel Taxotere  1995-11-27   
HospiraMitomycin Mitomycin  1995-11-29   
Bristol Myers SquibbMitomycin Mutamycin  1982-01-01   
Accord HealthcareDocetaxel Docetaxel Accord  2012-05-22   
Mitomycin Mitomycin  1998-04-30   
Hikma PharmaceuticalsMitomycin Mitomycin  1995-04-19   
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
84%
102/122
Phase 2
28%
55/197
Phase 3
16%
12/75
Approved: 3Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Docetaxel,
Globulin, immune
Mylan
Docetaxel
Sanofi
Docetaxel,
Tusamitamab ravtansine,
Aglatimagene besadenovec,
Lenograstim,
Sulodexide,
Molgramostim,
Aspartame,
Bevifimod,
Doxecitine,
Nadide,
Nepidermin,
Polyglycolic acid,
Telbermin,
Fludeoxyglucose f-18,
Globulin, immune,
Bos taurus adrenal cortex corticosteroids,
Krestin,
Cort-108297,
Folinoral,
For46,
Docetaxol,
Taxane
Bristol Myers Squibb
Mitomycin,
Rucaparib,
Fluorodopa f-18,
Rucaparib camsylate,
Gilvetmab,
Aglatimagene besadenovec,
Rigosertib,
Brivanib alaninate,
Lornoxicam,
SOTIGALIMAB,
Bevifimod,
Doxecitine,
Edodekin alfa,
Farletuzumab,
Nepidermin,
Polyglycolic acid,
Selicrelumab,
Telbermin,
URELUMAB,
Fludeoxyglucose f-18,
Globulin, immune,
Tj033721,
Docetaxol,
Fluoropyrimidine,
Hidroxicloroquina,
Taxane
Fresenius Kabi
Thiotepa
Astex Pharmaceuticals
Mitomycin
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use